Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
IONS: A Rule 144 notice reports planned and recent sales of Common Stock. The record lists 10,837 restricted shares tied to an 04/15/2022 award with a 04/15/2026 date and three reported open-market sales by Joseph Baroldi on 01/30/2026, 03/03/2026, and 04/16/2026.
Ionis Pharmaceuticals, Inc. is asking stockholders to vote at its 2026 virtual Annual Meeting on June 4, 2026. Stockholders of record as of April 7, 2026 may attend online, submit questions and vote using a 16-digit control number.
The agenda includes electing two directors, an advisory “say on pay” vote on executive compensation, and ratifying Ernst & Young LLP as independent auditors for fiscal 2026. Ionis also seeks approval to amend its 2011 Equity Incentive Plan to add 9,500,000 shares, bringing the plan total to 52,000,000 shares, and to amend its 2000 Employee Stock Purchase Plan to add 750,000 shares and remove the plan’s termination date.
The proxy materials describe the company’s classified board structure, committee responsibilities, risk oversight, executive team, corporate governance practices, and compensation philosophy, including increased use of performance-based restricted stock units, stock ownership guidelines, a clawback policy, and prohibitions on hedging and pledging company stock.
Ionis Pharmaceuticals reported additional positive results from its pivotal Phase 1-3 study of zilganersen in Alexander disease, a rare and often fatal neurological disorder with no approved disease‑modifying treatments. In patients aged ≥5, zilganersen 50 mg met the study’s primary endpoint by stabilizing gait speed on the 10‑Meter Walk Test at Week 61 versus control, showing a 33.3% least‑square mean difference (p=0.041). In children aged 2‑4, Gross Motor Function Measure‑88 results suggested improved gross motor function versus control. Multiple patient, caregiver and clinician‑reported secondary endpoints generally favored zilganersen, and an exploratory analysis showed a 33.6% reduction in plasma GFAP levels at Week 61 versus control. Safety was described as favorable, with serious treatment‑emergent adverse events less frequent than in the control group. Zilganersen is under FDA Priority Review with a Prescription Drug User Fee Act action date of September 22, 2026.
IONIS PHARMACEUTICALS INC director Lynne B. Parshall reported selling 5,000 shares of common stock in open-market transactions. The sales occurred on April 15, 2026 in two tranches: 4,466 shares at a weighted average price of $76.19 and 534 shares at a weighted average price of $76.97.
These trades were executed under a pre-arranged Rule 10b5-1 Trading Plan adopted on May 6, 2025, indicating they were scheduled in advance. Following the transactions, Parshall directly holds 51,344 shares of Ionis common stock.
Ionis Pharmaceuticals EVP Kyle Jenne reported routine equity compensation activity involving restricted stock units and common shares. On April 15, 2026, Jenne exercised 12,226 Restricted Stock Units, each representing a right to receive one share of Ionis common stock pursuant to a prior award.
In connection with this vesting, on April 16, 2026, Jenne completed an automatic sale of 4,902 common shares to cover required tax withholding obligations under the company’s equity incentive plan, at a weighted average price of $75.171 per share, with individual trades ranging from $75.06 to $75.26. Following these transactions, Jenne directly holds 23,713 shares of common stock and 74,402 Restricted Stock Units, which continue to vest in four equal annual installments.
Ionis Pharmaceuticals EVP Brian Birchler reported routine equity compensation activity and a related tax sale. He acquired 1,875 shares of common stock on conversion of Restricted Stock Units that vested under a prior award. The filing notes each RSU converts into one share of Ionis common stock.
To cover required tax withholding obligations from this vesting, 973 common shares were automatically sold at a weighted average price of $75.042 per share, with individual sale prices ranging from $75.01 to $75.06. After these transactions, Birchler directly holds 67,500 common shares, while 48,926 Restricted Stock Units remain outstanding and continue to vest in four equal annual installments.
IONIS PHARMACEUTICALS INC EVP and Chief Business Officer Joseph Baroldi reported RSU vesting and a related tax sale. On April 15, 2026, 10,837 Restricted Stock Units vested and were converted into 10,837 shares of common stock at a conversion price of $0.00 per share.
On April 16, 2026, 5,619 shares of common stock were sold at a weighted average price of $74.56 per share in an automatic sale to cover required tax withholding obligations under the company’s equity incentive plan. Following these transactions, Baroldi directly holds 46,535 common shares and has indirect ownership of 4,347 shares held by his spouse.
Ionis Pharmaceuticals reported Form 144 sales of Common Stock by brokers/dealers on behalf of insiders. The excerpt lists trades with share counts of 4,902, 1,823, and 37,277 executed on 01/16/2026, 03/10/2026, and related RSUs dated 04/15/2026.
Ionis Pharmaceuticals submitted a Form 144 notifying a proposed sale of 973 shares of Common Stock (issued as RSUs under the 2011 Equity Incentive Plan) through Morgan Stanley on 04/16/2026. The filing lists prior share sales in the past three months: 8,480 shares sold on 01/15/2026 for $636,932.80 and 6,179 shares sold on 01/30/2026 for $513,047.87.